TKTakeo Kuwata

Takeo Kuwata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeo Kuwata has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Shuzo Matsushita

    Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

    13 shared publications
  • Takamasa Ueno

    Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

    5 shared publications
  • Mikiko Shimizu

    Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

    4 shared publications
  • Hiroshi Morioka

    Department of Analytical and Biophysical Chemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

    3 shared publications
  • Kyo Okazaki

    Department of Analytical and Biophysical Chemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

    3 shared publications
  • Mako Toyoda

    Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

    3 shared publications

Latest Publications

  • Open Access

    Somatic Hypermutations Enhance Neutralization Breadth of IGHV3‐53/3‐66 Public Antibodies Against SARS‐CoV‐2 Variants

    by Takeo Kuwata, Kyo Okazaki, Hiroshi Morioka, Yu Kaku, Mikiko Shimizu, Yoshimi Maruyama, Ahmed K. Hamdy, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Tateki Suzuki, Takao Hashiguchi, et al.

    Objective: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continuously evolves to evade antibodies elicited by prior infection or vaccination. Most IGHV3‐53/3‐66 public antibodies potently neutralize the prototype strain, but show limited activity against recent variants. However, some acquire broad neutralizing activity through accumulation of somatic hypermutations. We assessed whether non‐broadly neutralizing IGHV3‐53/3‐66 antibodies could mature into broadly neutralizing antibodies. Methods: A series of mutant antibodies was constructed based on the IGHV3‐53/3‐66 antibodies, 9‐105 and K4‐66. Neutralizing and binding activities were compared with the original antibodies. Results: Introducing six mutations frequently observed in broadly neutralizing antibodies markedly improved the neutralization and binding of 9‐105 against Omicron variants. Introducing Y66F into K4‐66 enhanced neutralization of variants including BA.4/5 and JN.1. Conclusion: These findings show that mutations within the IGHV3‐53/3‐66 gene can enhance antibody breadth and potency, suggesting the potential of vaccine strategies to promote the maturation of these widely prevalent public antibodies.

  • Open Access

    Frequent Detection of HIV-1 Variants With Mixed Coreceptor Usage Among People Who Inject Drugs Infected With CRF01_AE: Possible Association With Coreceptor Switch

    by Yosuke Maeda, Takayuki Chikata, Takeo Kuwata, Hiromi Terasawa, Giang Van Tran, Shuzo Matsushita, Tomohiro Sawa, Futoshi Hasebe, Masafumi Takiguchi

    Background: Our previous study suggested that mixed infection with R5 and X4/dual human immunodeficiency virus type 1 (HIV-1) may contribute to coreceptor switch from R5 to X4 HIV-1. To confirm this hypothesis, we investigated mixed HIV-1 infections in people who inject drugs (PWID) infected with the CRF01_AE subtype. Methods: Viral plasma RNA from PWID were extracted, the V3 region of the HIV-1 gp120 gene was amplified, and deep sequencing was performed. Coreceptor usage was determined using phenotypic assay by cloning each V3 region. Coreceptor usage of minor HIV-1 variants detected by deep sequencing was predicted based on the amino acid sequences of the V3 region. Results: Deep sequencing of plasma from 36 PWID revealed that mixed HIV-1 infection involving different coreceptor usage occurred in 13 cases (36.1%). Phylogenetic analysis revealed that R5 variants were dominant, whereas X4/dual variants were detected as minor populations in most cases. In 1 case, however, R5 variants emerged as a distinct minor population mixed with X4/dual variants as the major population. Notably, plasma viral RNA load (pVL) was higher in cases of mixed infection with R5 and X4/dual HIV-1 than in those infected solely with R5 HIV-1. Conclusions: Our observations suggest a possible association between mixed HIV-1 coreceptor usage and coreceptor switch in CRF01_AE–infected PWID, and that mixed infection may be associated with pVL.

  • Open Access

    Robust and Reproducible Monoclonal Antibody Production Using a Transgenic Silkworm System

    by Seiki Yageta, Yudai Nagata, Mamoru Shimizu, Natsumi Yasaka, Takuma Iwasa, Takushi Nakajima, Takeo Kuwata, Shuzo Matsushita, Masahiro Tomita

    Transgenic silkworms are promising host organisms for the production of therapeutic recombinant proteins due to their superior protein synthesis ability and human-like posttranslational modifications. In this study, we generated transgenic silkworms that secrete a recombinant human monoclonal antibody (mAb) against gp120 of human immunodeficiency virus (HIV) into their cocoons. Variations in the rearing temperature and humidity conditions had little effect on mAb properties, such as N-glycosylation. Next, we performed pilot-scale production of the mAb using three batches of transgenic silkworms. Rearing 22,000–45,000 silkworm larvae yielded 4–8 kg of cocoon shells per batch. Larval growth and development, as well as cocoon quality, were highly consistent across production batches. We extracted and purified the mAb from cocoon shells, yielding 6.1–7.6 g of purified mAb per kg of cocoons in each batch. Characterization of the purified mAb showed that the contents of oligomeric antibodies and host cocoon-derived proteins were less than 0.2% and 10 ppm, respectively, with high consistency among batches. From these results, we conclude that the transgenic silkworm system is sufficiently robust and reproducible for high-quality therapeutic mAb production.


  • Open Access

    Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case

    by Takeo Kuwata, Yu Kaku, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami, Ryuta Uraki, Kyo Okazaki, Rumi Minami, Yoji Nagasaki, et al.


  • Open Access

    Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV

    by Isaac Ngare, Toong Seng Tan, Mako Toyoda, Takeo Kuwata, Soichiro Takahama, Eriko Nakashima, Naoya Yamasaki, Chihiro Motozono, Teruhisa Fujii, Rumi Minami, et al.

    People living with HIV (PLWH) could be at risk of blunted immune responses to COVID-19 vaccination. We investigated factors associated with neutralizing antibody (NAb) responses against SARS-CoV-2 and variants of concern (VOCs), following two-dose and third booster monovalent COVID-19 mRNA vaccination in Japanese PLWH. NAb titers were assessed in polyclonal IgG fractions by lentiviral-based pseudovirus assays. Overall, NAb titers against Wuhan, following two-dose vaccination, were assessed in 82 PLWH on treatment, whereby 17/82 (20.73%) were classified as low-NAb participants. Within the low-NAb participants, the third booster vaccination enhanced NAb titers against Wuhan and VOCs, albeit to a significantly lower magnitude than the rest. In the multivariate analysis, NAb titers against Wuhan after two-dose vaccination correlated with age and days since vaccination, but not with CD4+ count, CD4+/CD8+ ratio, and plasma high-sensitivity C-Reactive protein (hsCRP). Interestingly, an extended analysis within age subgroups revealed NAb titers to correlate positively with the CD4+ count and negatively with plasma hsCRP in younger, but not older, participants. In conclusion, a third booster vaccination substantially enhances NAb titers, but the benefit may be suboptimal in subpopulations of PLWH exhibiting low titers at baseline. Considering clinical and immune parameters could provide a nuanced understanding of factors associated with vaccine responses in PLWH.


  • Open Access

    Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2

    by Yosuke Maeda, Mako Toyoda, Takeo Kuwata, Hiromi Terasawa, Umiru Tokugawa, Kazuaki Monde, Tomohiro Sawa, Takamasa Ueno, Shuzo Matsushita

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19) and employs angiotensin-converting enzyme 2 (ACE2) as the receptor. Although the expression of ACE2 is crucial for cellular entry, we found that the interaction between ACE2 and the Spike (S) protein in the same cells led to its downregulation through degradation in the lysosomal compartment via the endocytic pathway. Interestingly, the ability of the S protein from previous variants of concern (VOCs) to downregulate ACE2 was variant-dependent and correlated with disease severity. The S protein from the Omicron variant, associated with milder disease, exhibited a lower capacity to downregulate ACE2 than that of the Delta variant, which is linked to a higher risk of hospitalization. Chimeric studies between the S proteins from the Delta and Omicron variants revealed that both the receptor-binding domain (RBD) and the S2 subunit played crucial roles in the reduced ACE2 downregulation activity observed in the Omicron variant. In contrast, three mutations (L452R/P681R/D950N) located in the RBD, S1/S2 cleavage site, and HR1 domain were identified as essential for the higher ACE2 downregulation activity observed in the Delta variant compared to that in the other VOCs. Our results suggested that dysregulation of the renin–angiotensin system due to the ACE2 downregulation activity of the S protein of SARS-CoV-2 may play a key role in the pathogenesis of COVID-19.


  • Idiotopes of antibodies against HIV‐1 CD4‐induced epitope shared with those against microorganisms

    by Shashwata Biswas, Takeo Kuwata, Soichiro Yamauchi, Kyo Okazaki, Yu Kaku, Zahid Hasan, Hiroshi Morioka, Shuzo Matsushita

    Induction of antibodies (Abs) against the conformational CD4‐induced (CD4i) epitope is frequent in HIV‐1 infection. However, the mechanism of development of anti‐CD4i Abs is unclear. We used anti‐idiotypic (aID) monoclonal Abs (mAbs) of anti‐CD4i mAbs to isolate anti‐CD4i mAbs from infected subjects and track the causative antigens. One anti‐aID mAb sorted from infected subjects by aID mAbs had the characteristics of anti‐CD4i Abs, including IGHV1‐69 usage and ability to bind to HIV‐1 Env enhanced by sCD4. Critical amino acid sequences for the binding of six anti‐aID mAbs, with shared idiotope to anti‐CD4i mAbs, were analysed by phage display. The identified amino acid sequences showed similarity to proteins from human microbiota and infectious agents. Peptides synthesized from Caudoviricetes sp and Vibrio vulnificus based on the identified sequences were reactive to most anti‐aID and some anti‐CD4i mAbs. These results suggest that anti‐CD4i Abs may evolve from B cells primed by microorganisms.


  • Open Access

    Differential Ability of S Protein of SARS-CoV-2 Variants to Downregulate ACE2

    by Yosuke Maeda, Mako Toyoda, Takeo Kuwata, Hiromi Terasawa, Umiru Tokugawa, Kazuaki Monde, Tomohiro Sawa, Takamasa Ueno, Shuzo Matsushita

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of corona-virus disease 19 (COVID-19) and employs angiotensin-converting enzyme 2 (ACE2) as the recep-tor. Although the expression of ACE2 is crucial for cellular entry, we found that the interaction of ACE2 with the Spike (S) protein in the same cells led to its downregulation through degradation in the lysosomal compartment via the endocytic pathway. Interestingly, the ability of the S protein from previous variants of concern (VOCs) to downregulate ACE2 was variant-dependent and correlated with disease severity. The S protein from the Omicron variant, associated with milder disease, exhibited a lower capacity to downregulate ACE2 than that of the Delta variant, which is linked to a higher risk of hospitalization. Chimeric studies between the S proteins from the Delta and Omicron variants revealed that both the receptor-binding domain (RBD) and S2 subunit played crucial roles in the reduced ACE2 downregulation activity observed in the Omicron var-iant. In contrast, three mutations (L452R/P681R/D950N) located in the RBD, S1/S2 cleavage site, and HR1 domain were identified as essential for the higher ACE2 downregulation activity ob-served in the Delta variant than that in the other VOCs. Our results suggested that dysregulation of the renin-angiotensin system due to the ACE2 downregulation activity of the S protein of SARS-CoV-2 may play a key role in the pathogenesis of COVID-19.

  • Open Access

    Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

    by Yu Kaku, Takeo Kuwata, Hasan Md Zahid, Takao Hashiguchi, Takeshi Noda, Noriko Kuramoto, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami, et al.


  • Open Access

    Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection

    by Yuto Nomura, Saori Matsuoka, Midori Okazaki, Takeo Kuwata, Tetsuro Matano, Hiroshi Ishii

    Antibody responses are crucial for the control of virus infection. Understanding of the mechanism of antibody induction is important for the development of a vaccine eliciting effective anti-virus antibodies. Virus-specific B cell receptor (BCR)/antibody repertoires are different among individuals, but determinants for this difference remain largely unclear. We have recently reported that a germline BCR immunoglobulin (IgG) gene polymorphism (VH3.33_ET or VH3.33_VI) in rhesus macaques is the determinant for induction of potent B404-class anti-simian immunodeficiency virus (SIV) neutralizing antibodies in neutralization-sensitive SIVsmH635FC infection. In the present study, we examined whether neutralization-resistant SIVsmE543-3 infection can induce the anti-SIV neutralizing antibodies associated with the germline VH3.33 polymorphism. Anti-SIVsmE543-3 neutralizing antibodies were induced in all the macaques possessing the VH3.33_ET allele, but not in those without VH3.33_ET, in the chronic phase of SIVsmE543-3 infection. Next generation sequencing analysis of BCR VH genes found B404-class antibody sequences only in those with VH3.33_ET. These results indicate that anti-SIVsmE543-3 neutralizing antibody induction associated with the germline BCR IgG gene polymorphism can be triggered by infection with neutralization-resistant SIVsmE543-3. This animal model would be useful for the elucidation of the mechanism of potent antibody induction against neutralization-resistant viruses.